transcripts

Transcript, Meeting 11, Session 4

DR. WAGNER: 

            We appreciate you all hanging around for a roundtable.  We have found these to be, uh, uh, very helpful, uh, although they tend to be extremely wide ranging and, uh, and I’m concerned that there isn’t – we try – in order to keep them from just going, spinning immediately out of control, we try to, uh, pose a framing question.  It’s very hard to pose a framing question for this one but, maybe we can start with something like this.

Date

Mon, 11/05/2012

Transcript, Meeting 11, Session 2

DR. WAGNER:  Let me invite our next session, experts forward, Bruce Lockwood, Dr. Benjamin. 

Date

Mon, 11/05/2012

Transcript, Meeting 11, Session 1

DR. WAGNER:  I believe we are assembled. I’m Jim Wagner.  It’s my privilege to be serving Emory University as its president.  I also am privileged to be the Vice Chair of this President’s Commission on the Study of Bioethical Issues.  Our chairman, Amy Gutmann, has asked me to convey, uh, regrets, at least for this first day of our meetings.  She had something come up on Saturday, uh which obligates her today and requires her attention today, but she’ll be flying in I believe this evening to be with us tomorrow.

Date

Mon, 11/05/2012

Transcript, Meeting 10, Session 2

DR. WAGNER:  Our next session is on protection of private and public genomic databases.  And if Dr. Chahine and -- Drs. Chahine and Rodriguez would come forward.  Wonderful.

                             We'll be hearing first from Dr. Ken Chahine.  He is the senior vice president of Ancestry.com, well known online resource for family history and general manager for Ancestry DNA where he leads the development and commercialization of population genetics at the website which is the same name, AncestryDNA.com. 

Date

Wed, 08/01/2012

Transcript, Meeting 10, Opening Remaks & Session 1

DR. GUTMANN:  Good morning, everybody.  I'm Amy Gutmann.  I'm president of the University of Pennsylvania and chair of the Presidential Commission for the Study of Bioethical Issues.  On behalf of my vice chair Jim Wagner who is president of Emory University and myself I welcome you all to this our tenth meeting.

                             Before we continue and in order for us to continue officially I want to recognize our designated federal officer, Dr. Lisa Lee.  Lisa, would you please stand up?  Lisa is the executive director of our Commission.  Thank you.

Date

Wed, 08/01/2012

Transcript, Meeting 10, Session 11

               DR. GUTMANN:  Thank you all for giving us such stimulating presentations.  And this is an opportunity for us to pick your brains one more time, and it's become a tradition to begin with a question of asking you to pinpoint one single issue that you think is most important, but I want to refine that question somewhat in light of your excellent presentations.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Session 10

                             DR. WAGNER:  Gentlemen, welcome. To our panelists, we have been eager ‑‑ I was going to say "agonizing" (laughter) ‑‑ but we have been eager to have more facts, more information, and to zero-in on what is the key information needed for decision-making regarding pediatric medical countermeasures research.  And we are hoping these speakers are going to help inch us ‑‑ in fact, feel free to move more than inch ‑‑ in this conversation, gentlemen.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Session 9

DR. GUTMANN:  I am going to get started because we have a wonderful guest.

                             Please take seats.

                             Our next session will focus on national-level review of certain types of pediatric research.  Initially contemplated in the late 1970s by one of our predecessor bioethics commissions, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, this type of national-level review is also codified in federal regulations.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Session 8

DR. WAGNER:  Okay.  If we can have the Commissioners take their seats?

                             And we will begin our Session 8, after a very productive Session 7.  Thank you, Amy.  That was excellent.

                             And so, at this point in our meeting, we do switch gears.  We have been talking about genomics and whole genomic sequencing.  We are going to shift to medical countermeasures.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Sessions 5 & 6

DR. GUTMANN:  Welcome back, everyone.  If you would please take a seat we will get started.  This is the beginning of a series of sessions in which we as members of the Commission will discuss in real potential form possible draft -- well, these are draft recommendations and we'll discuss them as a Commission. 

Date

Wed, 08/01/2012

Pages

Subscribe to RSS - transcripts